CDMO或可加速COVID-19候选疫苗的大规模生产

2020-08-03 Allan MedSci原创

作为生物制剂、病毒疫苗和基因疗法的合同开发与制造组织(CDMO),FUJIFILM Diosynth生物技术公司今日宣布,将支持COVID-19候选疫苗的生产。

作为生物制剂、病毒疫苗和基因疗法的合同开发与制造组织(CDMO),FUJIFILM Diosynth生物技术公司今日宣布,将支持COVID-19候选疫苗的生产,旨在开始向美国民众提供数百万剂安全有效的COVID-19疫苗。

FUOSFILM Diosynth生物技术公司于7月23日宣布与Novavax达成协议,在其位于北卡罗来纳州的工厂生产用于NVX-CoV2373的原料药。从北卡罗莱纳州向德克萨斯州的技术转让将于2020年末开始,候选疫苗的大规模生产将从2021年初开始。

FUJIFILM Diosynth生物技术公司首席运营官Gerry Farrell博士说:“我们的科学家和工程师很荣幸支持COVID-19疫苗的生产”。合同加工外包(CMO)主要是接受制药公司的委托,提供产品生产时所需要的工艺开发、配方开发、临床试验用药、化学或生物合成的原料药生产、中间体制造、制剂生产等服务。CDMO则是在CMO基础上衍生出的更为适应市场的形式。

 

原始出处:

https://www.firstwordpharma.com/node/1744005?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937300, encodeId=83fb193e300a4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 28 23:45:52 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043423, encodeId=94192043423fd, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Feb 20 17:45:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668817, encodeId=26fb166881e8d, content=<a href='/topic/show?id=df14441e81' target=_blank style='color:#2F92EE;'>#CDMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4417, encryptionId=df14441e81, topicName=CDMO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67c126449235, createdName=anminleiryan, createdTime=Mon Mar 15 09:45:52 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517828, encodeId=7e6b151e828d3, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562051, encodeId=422715620513d, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937300, encodeId=83fb193e300a4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 28 23:45:52 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043423, encodeId=94192043423fd, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Feb 20 17:45:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668817, encodeId=26fb166881e8d, content=<a href='/topic/show?id=df14441e81' target=_blank style='color:#2F92EE;'>#CDMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4417, encryptionId=df14441e81, topicName=CDMO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67c126449235, createdName=anminleiryan, createdTime=Mon Mar 15 09:45:52 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517828, encodeId=7e6b151e828d3, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562051, encodeId=422715620513d, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2021-02-20 ylz8403
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937300, encodeId=83fb193e300a4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 28 23:45:52 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043423, encodeId=94192043423fd, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Feb 20 17:45:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668817, encodeId=26fb166881e8d, content=<a href='/topic/show?id=df14441e81' target=_blank style='color:#2F92EE;'>#CDMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4417, encryptionId=df14441e81, topicName=CDMO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67c126449235, createdName=anminleiryan, createdTime=Mon Mar 15 09:45:52 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517828, encodeId=7e6b151e828d3, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562051, encodeId=422715620513d, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2021-03-15 anminleiryan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937300, encodeId=83fb193e300a4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 28 23:45:52 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043423, encodeId=94192043423fd, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Feb 20 17:45:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668817, encodeId=26fb166881e8d, content=<a href='/topic/show?id=df14441e81' target=_blank style='color:#2F92EE;'>#CDMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4417, encryptionId=df14441e81, topicName=CDMO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67c126449235, createdName=anminleiryan, createdTime=Mon Mar 15 09:45:52 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517828, encodeId=7e6b151e828d3, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562051, encodeId=422715620513d, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1937300, encodeId=83fb193e300a4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 28 23:45:52 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043423, encodeId=94192043423fd, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Feb 20 17:45:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668817, encodeId=26fb166881e8d, content=<a href='/topic/show?id=df14441e81' target=_blank style='color:#2F92EE;'>#CDMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4417, encryptionId=df14441e81, topicName=CDMO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67c126449235, createdName=anminleiryan, createdTime=Mon Mar 15 09:45:52 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517828, encodeId=7e6b151e828d3, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562051, encodeId=422715620513d, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Thu Jul 30 00:45:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]

相关资讯

苏桥生物与启德医药签订战略合作协议

6月5日,国际领先的生物医药一站式CDMO服务平台,苏桥生物(苏州)有限公司(简称“苏桥生物”)宣布与启德医药科技(苏州)有限公司(简称“启德医药”)签订战略合作协议。在战略合作框架下,双方将充分利用各自在生物药定制开发与生产(CDMO)以及国际ADC创新药研发方面的优势,确保启德医药创新药从临床阶段开发到上市的高速推进,为全球肿瘤病患提供更为高效、安全的治疗药物。

拓展阅读

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

法国特种疫苗公司Valneva已完成其灭活的佐剂型COVID-19疫苗VLA2001的I / II期研究的患者招募工作,预计将于2021年4月发布初步数据。

COVID-19候选疫苗SN14将进入临床试验

制药公司Scancell的COVID-19候选疫苗SN14将进入临床试验阶段。Scancell的DNA疫苗旨在靶向树突状细胞,以刺激高亲和力的T细胞,这些T细胞能够识别并破坏患病细胞。

NEJM:COVID-19候选疫苗mRNA-1273的临床前研究,效果明显!

生物技术公司Moderna是信使RNA(mRNA)治疗剂和疫苗的先驱,Moderna今日公布了一项临床前研究,旨在评估COVID-19候选疫苗mRNA-1273,其结果发表在《NEJM》上。

COVID-19候选疫苗(PittCoVacc,匹兹堡冠状病毒疫苗):动物实验显成效

美国匹兹堡大学医学院的一项研究显示,一款针对新冠病毒的候选疫苗在小鼠中进行了测试,通过指尖大小的贴片递送的疫苗会产生针对新冠病毒的特异性抗体,其数量足以中和病毒。